IDEAYA reports positive phase 2/3 trial results for uveal melanoma drug

June 1, 2026 11:00 AM

IDEAYA Biosciences Inc. (NASDAQ: IDYA) and Servier reported results from their phase 2/3 OptimUM-02 trial of darovasertib in combination with ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found